Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

GSK PLC Sponsored ADR (GSK) vs Novo Nordisk A/S (NVO)

GSK PLC Sponsored ADR and Novo Nordisk A/S are both Drug Manufacturers General companies. Novo Nordisk A/S is the larger, with a market value of $129.3B against $100.1B — 1.3× the size. Novo Nordisk A/S trades at the lower P/E: 9.5× against 15.3×. Novo Nordisk A/S grew revenue faster over the last twelve months: 13.2% against 8.72%. Novo Nordisk A/S has the higher net margin (35.5% vs 14.6%) and the higher return on invested capital (28.7% vs 12.6%). Both pay a dividend; GSK PLC Sponsored ADR yields more (3.66% vs 1.36%). Across the 23 metrics below, Novo Nordisk A/S leads on 15 and GSK PLC Sponsored ADR on 8.

Valuation

Metric GSK NVO Drug Manufacturers General median
P/E 15.34 9.49 24.72
P/S 2.22 3.34 3.35
P/B 4.29 5.00 5.00
Price to free cash flow 12.92 22.61 17.68
EV/EBITDA 9.30 7.04 13.91
EV/Sales 2.67 3.62 3.95
Earnings yield 6.52% 10.54% 2.92%
Free cash flow yield 7.74% 4.42% 4.42%

Profitability

Metric GSK NVO Drug Manufacturers General median
Gross margin 72.75% 80.73% 72.77%
Operating margin 19.55% 43.36% 18.90%
Net margin 14.58% 35.47% 8.27%
Free cash flow margin 17.18% 14.79% 17.25%
Return on equity 30.74% 60.84% 6.97%
Return on assets 8.01% 22.00% 2.76%
Return on invested capital 12.58% 28.67% 6.30%

Growth

Metric GSK NVO Drug Manufacturers General median
Revenue growth (TTM) 8.72% 13.15% 6.79%
EPS growth (last fiscal year) 133.96% 6.40% —
Revenue growth, 5-year CAGR (0.32%) 19.20% 3.98%
Net income growth, 5-year CAGR 0.42% 19.16% 0.42%

Health

Metric GSK NVO Drug Manufacturers General median
Debt to equity 1.06 0.63 0.63
Current ratio 0.82 0.87 1.32
Net debt to EBITDA 1.39 0.65 1.15

Dividend

Metric GSK NVO Drug Manufacturers General median
Dividend yield 3.66% 1.36% 3.57%
Payout ratio 0.46 0.41 0.53

Size

Metric GSK NVO Drug Manufacturers General median
Market cap 100.08b 129.28b 125.91b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack